



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 37/00* (2006.01)
C07D 519/00 (2006.01) *A61P 29/00* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2013/058614

(22) International Filing Date:

6 September 2013 (06.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/699,038 10 September 2012 (10.09.2012) US
 61/728,693 20 November 2012 (20.11.2012) US
 61/782,605 14 March 2013 (14.03.2013) US

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US];
 400 East Jamie Court, Suite 302, South San Francisco, CA
 94080 (US).

(72) Inventors: **OWENS, Tim**; 5 Pyxie Ln, San Carlos, CA
 94070 (US). **VERNER, Erik**; 1521 Notre Dame Avenue,
 Belmont, CA 94002 (US).

(74) Agent: **RODRIGO, Christina, M.**; Finnegan, Henderson,
 Farabow, Garrett & Dunner, LLP, 901 New York Avenue
 NW, Washington, DC 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS



(IA)

(57) Abstract: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.